PROGRAF AVERAGE DAILY COST Of $18.31 AT MAINTENANCE DOSES
PROGRAF AVERAGE DAILY COST Of $18.31 AT MAINTENANCE DOSES was estimated based on a retrospective analysis of clinical data from the pivotal study of Fujisawa's recently approved immunosuppressant agent. Prograf (tacrolimus, FK-506) was launched in June at a price of $2.18 per milligram AWP. Based on the average .12 mg/kg dose being used in patients at day 330 post- transplant, the study found that the average drug cost per day for a 70 mg patient would be $18.31 or an annualized cost of $6,683.15. The analysis was performed by the Boston consulting firm Putnam Associates on behalf of Fujisawa.
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
The reductions across medical product programs in the agency’s budget request include hundreds of positions funded by user fees, which may foreshadow its upcoming user fee restructuring strategy.
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
A European Medicines Agency official provided an overview and update of the support the EMA offers developers of innovative products and discussed, among other things, its Innovation Task Force, Quality Innovation Group and a scientific advice pilot for clinical trials.